MPTP l-methyl-4-phenyl

IRD infantile Refsum disease MPTP l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine... 

BRCT BRCAl C-terminus-like DBD DNA-binding domain dPARP Drosophila PARP MPTP l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine NAD+ Nicotinamide adenine dinucleotide NAm Nicotinamide NLS Nuclear locahzation signal OAADPR O-acetyl-ADP-ribose PAR Poly(ADP-ribose) PARG Poly(ADP-ribose) glycohydrolase PARP Poly(ADP-ribose) polymerase PARylation poly(ADP-ribosyl)ation... 

Forno LS, Langston JW, Irwin I, Langston EB (1984) Pathology of experimental parkinsonism in the squirrel-monkey - short-term effects of intraperitoneal administration of mptp (l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine). JNEN 43 349. 

JGA juxtaglomerular apparatus MPTP l-methyl-4-phenyl-l,2,3/6-tetrahydropyri-... 

In the late 1970s a substantial clue to the cause of the nerve cell destruction in Parkinson s disease was provided by young drug addicts using the synthetic heroin substitute MPPP (l-methyl-4-phenyl-4-proprionoxypiperidine) (Figure 14B). Several unfortunate individuals, later found to have consumed MPPP, were diagnosed with Parkinson s disease despite their youth and lack of a family history of the disease. Considerable research revealed that under certain reaction conditions the synthesis of MPPP produces a toxic by-product called MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine). Once it has been consumed, MPTP is converted to MPP+ (l-methyl-4-phenylpyridinium) in the brain by the enzyme monoamine oxidase. After its synthesis, MPP+ is transported by a... 

Parkinson s disease can be modeled in rodents and primates by systemic administration of the selective dopaminergic neurotoxin MPTP (l-methyl-4-phenyl-l, 2,3,6-tetrahydropyridine) or intracerebral administration of... 

MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) was administrated to adult, male cats to model Parkinson s disease (PD), and MRI and spectroscopy (MRS) at 1.5 T was utilized to identify metabolic degenerative changes in the striatum in vivo. " Neurological status and somatosensory-evoked potentials in vivo, as well as postmortem striatal histopathol. and immunohistochem. par-... 

A piperidine derivative, P-eucaine (56), is used as a local anesthetic. The illegal designer drug MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine, 57) contains the six-membered ring heterocycle and is particularly dangerous because it is converted to a metabolite, pyridinium salt 58 (MPP), in the body. This metabolite is associated with irreversible Parkinsonism. MPP is classified as a dopaminergic neurotoxin. 

---